Poseida Therapeutics, Inc. Stock Price, News & Analysis

Poseida Therapeutics (Nasdaq: PSTX) announced the appointment of George M. Church, Ph.D., to lead its newly established Gene Therapy Scientific Advisory Board (SAB). Dr. Church's extensive experience in genome engineering will guide Poseida's research in developing gene therapies for rare diseases, including ornithine transcarbamylase deficiency and Hemophilia A. This advisory board, alongside the Immuno-Oncology SAB, aims to enhance the company's innovations in gene editing and therapeutic solutions.

Poseida Therapeutics (PSTX) announced a peer-reviewed publication validating its Cas-CLOVER Site-specific Gene Editing System for producing allogeneic CAR-T cells. The research demonstrates that Cas-CLOVER achieves a high percentage (45%-70%) of T stem cell memory (T_scm) cells with significantly lower off-target activity (0.012%-0.089%) compared to other technologies like CRISPR. This advancement may enhance clinical responses and tolerability in cancer treatments. The publication appears in the September 2022 issue of Molecular Therapy – Nucleic Acids.

Poseida Therapeutics (Nasdaq: PSTX) will hold its virtual Annual Meeting of Stockholders on June 16, 2022, at 1:00 p.m. PT. Stockholders recorded as of April 20, 2022, can participate in the meeting via a live webcast. An online portal is available for stockholders to view proxy materials and vote shares in advance. Registration is required by June 14, 2022, and the meeting's website opens at 12:45 p.m. PT on the meeting day. Poseida focuses on creating innovative gene and cell therapeutics using proprietary technologies.

Poseida Therapeutics presented promising preclinical data on P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting, showcasing its potential as a safer preconditioning agent for hematopoietic stem cell (HSC) transplants. The data indicates that P-ckit-ALLO1 effectively eliminates over 95% of HSPCs and enhances survival in acute myeloid leukemia (AML) models. Utilizing advanced genetic technologies, P-ckit-ALLO1 could serve dual purposes: improving HSC transplant outcomes and acting as an anti-tumor therapy, presenting a less toxic alternative compared to existing treatments.

Poseida Therapeutics (Nasdaq: PSTX) announced its Q1 2022 financial results, reporting revenues of $1.4 million, up from $0 in Q1 2021, attributed to a collaboration with Takeda. However, net loss increased to $58.1 million compared to $38.3 million in 2021. R&D expenses rose to $48.9 million due to increased clinical activities and manufacturing capacity reductions. The company's cash position stands at $183.5 million. Poseida is advancing multiple CAR-T and gene therapy programs, with plans for clinical data updates later in 2022.

Poseida Therapeutics (Nasdaq: PSTX) announced that it will present preclinical data on its anti-c-kit CAR-T cell therapy, P-ckit-ALLO1, at the ASGCT 25th Annual Meeting in Washington, D.C., from May 16-19, 2022. This therapy aims to improve hematopoietic stem cell transplants by demonstrating a specific, less toxic conditioning regimen. The research highlights the potential for treating acute myeloid leukemia (AML) and enhancing HSC engraftment. The poster presentation is scheduled for May 17, 2022, at 5:30 PM ET.

Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced that CEO Mark Gergen will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 2:40pm PT in Las Vegas. The live presentation can be accessed via a webcast on Poseida's website, with a replay available for 30 days post-event. Poseida is focused on developing innovative cell and gene therapeutics using proprietary technologies like the non-viral piggyBac® DNA Delivery System and Cas-CLOVER™ gene editing, aimed at addressing limitations in current therapies.

Poseida Therapeutics (PSTX) reported Q4 and full-year 2021 financials, showcasing $31.2 million in revenue from a collaboration with Takeda, a significant increase from zero revenue in 2020. R&D expenses rose to $39.1 million for Q4, up from $27.9 million year-over-year, contributing to a net income of $1.5 million compared to a net loss of $36.1 million in Q4 2020. As of December 31, 2021, cash reserves were $206.3 million. Key developments include IND clearance for P-MUC1C-ALLO1 and initial clinical data expected in H2 2022.

Poseida Therapeutics (PSTX) announced an inducement award to Brent Warner, its new President of Gene Therapy, as part of its 2022 Inducement Plan. The award includes a stock option for 431,034 shares, with a vesting schedule over four years, and a restricted stock unit covering 307,881 shares with similar vesting terms. The exercise price of the stock option will equal the market value on the grant date. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain key talent within the company.